Novo Nordisk’s Wegovy approved by MHRA in the UK for cardiovascular prevention
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Novo Nordisk’s weight loss drug, Wegovy, for the prevention of serious cardiovascular events in overweight and obese adults. This landmark decision marks the first time a GLP-1 obesity drug is prescribed for such a purpose in the UK, following a similar approval by the